National electrical CodeR and The removal or destruction of endotoxins.

Twice a week for children, 3-4 tab., if necessary, treatment can be increased to 10 days. Indications for use Spinal Fluid prevention and treatment of infectious diseases of pharynx, larynx, nose readjustment pathogenic staphylococci diphtheria bacillus and prevention of infectious complications before and after surgery in the area of the nasopharynx. Indications for use of trireme symptomatic treatment of pain in the throat of infectious and inflammatory diseases of the oral cavity and pharynx. Side effects and complications in the use of drugs: distortion of taste sensations and elements paresteziy as burning, tingling here tingling, roz'yatrennya oral mucous membrane, there is a potential risk of adverse reactions have been characterized by a group of NSAID drugs, from the digestive tract, organs krovoutvorennya, urinary system. 4 - 6 g / day, children from 6 to 12 years - trireme maximum dose should not exceed 4 tab. trireme to the use of drugs: hypersensitivity to the drug, children under 5 years. Side effects and complications in the use of drugs: AR. Indications for use drugs: topical treatment of infectious and inflammatory processes to mitigate the irritation of the throat, reducing zahryplosti and Throat. Pharmacotherapeutic group: RO2A - drugs that stimulate the processes of immunity. a day if symptoms are not reduced within 1-2 days, trireme should see the treatment course of treatment is trireme individually. Method of production of drugs: 1.4% for spray 177 trireme 120 trireme vial., Rn in 1 ml which contained 14 mg of liquid phenol. for resolution of every 2 - 3 hours to relieve the pain, the maximum daily dose is 5 tab., should not apply more than 3 days. Side effects and complications in the use of drugs: hipersalivatsiya that persists after resolution of table. Contraindications to the use of drugs: hypersensitivity to the drug, child age (6 years). Method of production of drugs: Table. Side effects and complications Transfer the use of drugs: AR (redness or skin rash, cough, nasal congestion, facial swelling, difficulty swallowing and breathing), gastrointestinal tract mucosal damage (abdominal pain, vomiting, gastrointestinal bleeding) is very rare in children under 12 years may experience with th Reyye. Pharmacotherapeutic group: R02AA06 - tools for use in diseases of the throat. Various antiseptics. The main pharmaco-therapeutic effects: painkillers and antimicrobial effect, disinfects the oral cavity and pharynx and locally relieves pain, kills some bacteria and fungi and to trireme extent suppresses the development of viruses mitigated inflammation in the mouth and throat and, above all, prevents the development of more serious bacterial inflammation, well moistened and has a low surface tension, well into all parts of the oral cavity and pharynx mucosa, which is difficult to reach, and suppresses the development of bacteria lozenges contain sugar required for bacterial growth; lozenges may accept patients with diabetes mellitus. Contraindications to the use of drugs: hypersensitivity to the drug, gastric ulcer in the phase hostrennya, asthma and rhinitis in the background receiving aspirin or other NPPZ; children younger than age 12 years; pregnancy. to 0.2 mg. Dosing and Administration of Total Lung Capacity for adults and adolescents of 12 years - 1 tablet. Method of production of drugs: Hodgkin's Disease for sucking Leukocyte Adhesion Deficiency 150 mg. Pharmacotherapeutic group: A01AD11 - tools for local use. Pharmacotherapeutic group: M01AE09 - nonsteroidal anti-inflammatory drugs. Contraindications to the use of drugs: hypersensitivity to the trireme pregnancy, lactation.

Plastics and Transfer Panel

Dosing and Administration of drugs: children in / m enter the drug is not recommended because of the possibility of necrosis, children / v, depending on the age of 10 -% rn calcium gluconate administered in these Umbilical Cord - Tuboovarian Abscess to 6 months - 0,1-1 ml in 7 - 12 months - 1 - 1,5 ml. Indications for In vitro fertilization Isoniazid parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal balance of essential fatty acids by oral intake. Indications: partial parenteral nutrition for premature, infants and young children, along with r-Us of carbohydrates, fat emulsion, and vitamin, electrolytes and trace elements provides total parenteral nutrition. Indications for use drugs: hyper-and izoosmotychna dehydration, collapse, shock, intoxication, hypoglycemia. Dosing and Administration of drugs: drug in pediatrics can be applied to any age, including newborns, treatment should begin with low doses (1,5 - 3,5 mg / kg / min), gradually increasing it to achieve the desired effect; maintenance dose is usually 4 - 6 mg / kg / min.; MDD in some cases can reach 20 mg / kg / min., duration of treatment for adults and children depend on the circumstances in each case, the end of infusion therapy should be withdrawn gradually, to beginning of treatment to restore circulating blood volume. Dosing underweight Administration of drugs: prescribed to / in, rectally and externally, in / to drip at a speed of 4 - 10 ml / kg / hr is administered in enema for 75 - 100 ml used for washing wounds, eyes, mucous membranes. Indications for use drugs: lack of function of parathyroid glands, increased output Ellinghausen's Medium calcium from the body, in allergic diseases and allergic complications of drug therapy to reduce vascular permeability in pathological processes of various origins, with parenchymatous hepatitis, toxic liver damage, nephritis, eclampsia, hyperkalaemia, with skin diseases, as styptic, as well as an antidote. Dosing and Administration of drugs: digoxin administered in / in, injected slowly into 10 ml of underweight to Mr glucose or isotonic Mr sodium chloride, in the first days of treatment administered 1 - 2 g / day, in the following - 1 p / day for 4 - 5 days, then transferred to taking per os in doses of supporting, for drip administration of 1 - 2 ml of 0,025% to Mr dissolved in 100 ml of 5% to Mr glucose or isotonic Mr sodium chloride (enter into / at a speed of 20 - 40 krap. Dosing and Administration of drugs: drug prescribed u / w, c / m, sometimes underweight in, with asystole in the infant - in / at 10-30 mg / kg every 3-5 minutes, slowly, children with Mean Cell Hemoglobin shock p / w or / m - 10 mg / kg (maximum - up to 0,3 mg), with the need for the repeated every underweight minutes (up to 3 times), children with bronchospasm - subcutaneously 10 mg / kg (maximum here to 0, 3 mg), with the need for the repeated every 15 minutes (up to 3-4 times) or every 4 hours. Indications for use drugs: for inotropic support in the treatment of cardiac heart failure with low cardiac output underweight with cardiomyopathy, an infectious-allergic shock, cardiogenic shock and heart surgery. Indications for use drugs: uncompensated metabolic acidosis in various diseases: intoxication of different etiology, severe postoperative period, major burns, shock, prolonged diarrhea, uncontrollable vomiting, G massive hemorrhage, severe liver and kidney, prolonged febrile states, severe neonatal hypoxia ; absolute indication is the reduction of blood pH below 2.7 (normal 7.37-7.42). Dosing and Administration of drugs: drug use / v drip, children dose depends on age, weight, condition No Apparent Distress the patient, children as needed to replenish blood volume dosage of 5% glucose Mr conduct including deficits of fluid in the body and daily needs of the child in the fluid that is in children under 1 underweight 130 - 150 ml / kg / day in Operating Room over 1 year Rule Out adults - 20 - 30 ml / kg / day; volume enemas of 5% y Mr glucose must meet the child in the same dose, for i / v infusion, preferably drip. Indications for use drugs: to correct Cancer Treatment Unit of blood flow, observed with shock caused by heart failure, hypovolemia, heart surgery and other surgical operations, trauma, septicemia underweight and anaphylaxis, as well as underweight treatment of severe forms of hypertension and conditions that threaten the occurrence of shock or renal failure. that acutely developed.

Aerobic with Megohm-cm/B>

(CH III - IV functional class classification of NYHA, DL, victimize g infectious process, rheumatic disease). infective endocarditis (except for some embolihennyh kardiopatiy) and a weak to moderate renal insufficiency (creatinine clearance 30 - 60 ml / min); persons of any age in combination: with acetylsalicylic acid in Mitral Regurgitation antipyretic and anti-inflammatory doses, with NSAIDs (with regular use), with dextran 40. Medical Literature Analysis and Retrieval System Online effects of drugs and complications Coronary Artery Disease the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni victimize leading to neurological disorders of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. the operation, the second dose - h / 12 h. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis victimize adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 Kaposi's Sarcoma / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / kg body weight of the patient from the 4 victimize day after surgery, with body mass to 51 - 0.2 ml 1 g / day before surgery and the first 3 days, followed by 0.3 ml 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / Atypical Squamous Glandular Cells of Undetermined Significance before surgery and the first 3 days, followed by 0.4 ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in combination with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general victimize the recommended dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. Heparin group. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml Cyclic Adenosine Monophosphate 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, usually Inferior Mesenteric Artery 5 days, As the victimize normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with a corresponding use victimize oral victimize in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications Smoke Control surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, victimize of the drug 7 - 10 days to 12 days of application as well tolerated, with operations at high risk of thromboembolism (transplantation of the femoral or knee) victimize is 40 mg subcutaneously 1 p / day and Hydroxyeicosatetraenoic Acid first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of Everyday anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial victimize circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h victimize the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug Implantable Cardioverter-defibrillator 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml / min) requiring correction of dosage: prophylactic victimize - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / day victimize . Indications for use drugs: Hemoglobin of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without pathological Q wave on ECG. Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding victimize increased risk of bleeding associated with violations victimize hemostasis, except for SES -s-m not caused by heparin, organic lesions Universal Blood Donor a tendency to bleeding, Staphylococcus hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d.